ChipDX, Signal Genetics deal

Signal Genetics will acquire all of ChipDX's assets, including patents for prognostic tests in development for lung, breast and colon caners. Signal also gains ChipDX's web-based interface, which the company said will be used to enhance Signal's physician web portal and to allow for remote interpretation of test algorithms. ChipDX's CEO and founder, Ryan VanLaar, will join Signal as the head of bioinformatics. Details were not disclosed. ...